Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 3/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.48 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10097356 | 0.90 | ALDH1A1 (0.53) | MAPK13MAPK12MAPK11MAPK14KDM4E | |
| SCHEMBL10097329 | 0.90 | MAPK13 (0.61) | MAPK13MAPK12MAPK11MAPK14KDM4E | |
| SCHEMBL10097343 | 0.90 | PIM1 (0.50) | MAPK13MAPK12MAPK11MAPK14SERPINE1 | |
| SCHEMBL10097344 | 0.84 | MAOA (0.51) | MAPK13MAPK12MAPK11MAPK14KDM4E | |
| SCHEMBL10097345 | 0.83 | MAOA (0.50) | MAPK13MAPK12MAPK11MAPK14KDM4E | |
| SCHEMBL10097312 | 0.81 | MAOA (0.48) | MAPK13MAPK12MAPK11MAPK14KDM4E | |
| SCHEMBL10097330 | 0.81 | MAOA (0.48) | MAPK13MAPK12MAPK11MAPK14KDM4E | |
| SCHEMBL10097691 | 0.81 | MTNR1A (0.46) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL5618530 | 0.80 | MAPK1 (0.59) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL15058476 | 0.80 | HTR1A (0.55) | KDM4EALDH1A1HPGDKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-8013006-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7868037-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | MAPK13 4455/4885MAPK12 4026/4885MAPK11 4447/4885 |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | MAPK13 3283/4885MAPK12 2714/4885MAPK11 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.